Skip to main content

Follow-Up of Patients Administered with Gene Therapy Medicinal Products (EMEA/CHMP/GTWP/125459/2006)

 The document with the reference "EMEA/CHMP/GTWP/125459/2006" is related to a guideline issued by the European Medicines Agency (EMA) and the Committee for Medicinal Products for Human Use (CHMP) regarding the "Follow-Up of Patients Administered with Gene Therapy Medicinal Products." This guideline provides recommendations and regulatory guidance on how to conduct long-term follow-up of patients who have been treated with gene therapy medicinal products. Here is a more detailed explanation of the key points covered in this guideline:


1. Objective and Purpose:

The primary objective of this guideline is to ensure the long-term safety and efficacy monitoring of patients who have received gene therapy medicinal products. It recognizes the importance of ongoing assessment beyond the initial clinical trials and regulatory approval.

2. Applicability:

The guideline is applicable to a wide range of gene therapy products, including those using viral vectors, non-viral vectors, or genetically modified cells. The principles outlined in the guideline can be adapted to various types of gene therapy.

3. Duration of Follow-Up:

The guideline acknowledges that the duration of follow-up may vary depending on several factors, such as the nature of the gene therapy product, the disease being treated, and the potential risks associated with the therapy. It emphasizes the importance of defining the appropriate duration of follow-up in advance.

4. Safety Monitoring:

The document underscores the need for rigorous safety monitoring during the long-term follow-up period. This includes ongoing surveillance for adverse events and the assessment of any potential long-term safety concerns associated with gene therapy.

5. Efficacy Assessment:

In addition to safety monitoring, the guideline addresses the evaluation of long-term therapeutic efficacy. This involves assessing the durability of therapeutic effects and determining whether additional treatments or interventions may be needed over time.

6. Immunogenicity:

The guideline recognizes the potential for immunogenic responses to gene therapy products. It emphasizes the importance of monitoring and managing immunogenicity, as it can impact both safety and efficacy.

7. Data Collection and Reporting:

The document provides recommendations for data collection during long-term follow-up. This includes the establishment of patient registries, post-authorization studies, and the reporting of relevant data to regulatory authorities.

8. Risk-Benefit Evaluation:

The guideline stresses the ongoing risk-benefit evaluation of gene therapy products. If new safety or efficacy concerns arise during follow-up, regulatory authorities may need to reevaluate the benefit-risk profile of the therapy.

9. Communication:

Effective communication among regulatory authorities, marketing authorization holders, healthcare providers, and patients is emphasized. This communication is crucial for ensuring that all stakeholders are informed about any emerging safety or efficacy issues.

10. Quality Assurance:

- The document addresses the need for maintaining the quality and consistency of gene therapy products throughout the follow-up period. This includes ensuring the stability and reliability of the product.


In summary, this guideline sets out a framework for the long-term follow-up of patients treated with gene therapy medicinal products. It recognizes the dynamic nature of gene therapy and the importance of ongoing assessment to ensure patient safety and treatment efficacy. The guideline aims to provide regulatory authorities, healthcare providers, and manufacturers with guidance on how to conduct and manage the long-term follow-up process effectively. It reflects the evolving regulatory landscape in the field of gene therapy and emphasizes the importance of post-authorization activities to protect patient well-being. Specific details may have evolved since the guideline's issuance, so it is essential to consult the most up-to-date version of the guideline on the EMA's official website or through regulatory authoritie

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

Guideline on development and manufacture of lentiviral vectors (CHMP/BWP/2458/03)

The guideline with the reference number "CHMP/BWP/2458/03" pertains to the "Guideline on Development and Manufacture of Lentiviral Vectors." This guideline was developed by the Committee for Medicinal Products for Human Use (CHMP) and the Biotechnology Working Party (BWP) of the European Medicines Agency (EMA). It provides recommendations and regulatory guidance for the development and manufacture of lentiviral vectors, which are widely used in gene therapy and cell therapy applications. Here's an overview of the key points covered in this guideline: 1. Introduction: The guideline begins with an introduction highlighting the increasing importance of lentiviral vectors in advanced therapies and the need for guidance on their development and manufacture. 2. Scope: It defines the scope of the guideline, which covers the development and manufacture of lentiviral vectors intended for use in gene therapy and cell therapy products for human use. 3. Quality and Characte...
Read more

Stem-Loop PCR for siRNA

 Stem-loop PCR is a method often used for detecting and quantifying small RNAs, such as siRNA or miRNA, which are typically difficult to amplify directly due to their short lengths. The method involves the design of a stem-loop reverse transcription (RT) primer, which enhances specificity and stability of the short RNA during the RT-PCR process, allowing for sensitive detection and quantification of the siRNA. Here’s a detailed guide to how stem-loop PCR can be applied to siRNA detection: Key Steps in Stem-Loop PCR for siRNA Designing the Stem-Loop RT Primer : Structure : The stem-loop RT primer consists of a loop region flanked by complementary sequences on either side (the "stem"), which will fold back on itself to form a hairpin structure. Specific Binding Region : A short sequence complementary to the 3’ end of the siRNA is added at the end of the stem-loop primer to ensure specific binding to the siRNA target. Stabilization : The loop structure helps prevent primer-dimer...
Read more

FDA Guidance on Studying Multiple Versions of Cellular or Gene Therapy Products in Early-Phase Clinical Trials

 The purpose of this guidance is to offer advice to sponsors interested in conducting early-phase clinical trials for a single disease involving multiple variations of a cellular or gene therapy product. Sponsors aim to gather preliminary safety and efficacy data for these product variations within a single clinical trial. It's important to note that even though multiple product versions are studied together, each version is distinct and typically requires a separate investigational new drug application (IND) submission to the FDA. The primary goal of these early-phase clinical studies is to inform decisions about which product version(s) should be advanced for further development in later-phase trials. As such, these studies are not designed to provide the main evidence of effectiveness needed for a marketing application. They are generally not statistically powered to demonstrate a significant difference in efficacy between the different study arms. In this guidance, the FDA prov...
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quanti...
Read more